Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Sergio H who wrote (2214)	6/13/2003 2:00:53 PM
From: Jibacoa	Read Replies (1) \| Respond to of 23958

Sergio: I don't have any significant position on CLGY, but still hold some shares. It seems to be acting well and today is trading over its June Hs after it went through its March, April & May Hs on June 2. It is good that the insiders and institutions have made significant recent purchases. I also like the news last week on their licensing the patents for Nitric Oxide donors compositions. After I read the article from Cook et Al (from Stanford) quite a few years ago on the "green Journal" (The Am.J.of Med.)I have been taking some 500mgs of L-Arginine daily.<g> Although the experiments were done in the rabbit, I think they were quite impressive, as the controls developed severe atheromatous lesions on the aorta and major vessels, and the treated animals on the same atherogenic diet remained free of lesions. The only problem is that L-Arginine is like aspirin or Vitamin E. The Pharmaceutical Cos. don't have any incentive in promoting the use and prefer to promote the statins.<g> Will keep an eye on ALVR also. ( I wasn't sure if I had recommended it to the folio.) I am still long a few Ks on it. siliconinvestor.com BTW, Revere has 3 "different"<g> reports on CLGY today. "Drug/Medical Device Report: Approved & Pipeline Products offers a specific examination of a biopharmaceutical or medical devices company's product line including indications, side effects, and regulatory/clinical stage. Viewing these details of the product and its life cycle is key in assessing innovation and/or providing a competitive advantage for pharmaceutical companies. This report does not include any buy, sell or hold recommendations'. RAGL Bernard